 | |
 | |
| Company type | Aktieselskab |
|---|---|
| Nasdaq Copenhagen: NZYM B | |
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | Bagsværd, Denmark |
Key people |
|
| Products | Enzymes, microorganisms, biopharmaceutical ingredients |
| Revenue |  17.5 billion kr. (2022)[1] |
| 4.56 billion kr. (2022)[1] | |
| 3.69 billion kr. (2022)[1] | |
| Total assets | 27.9 billion kr. (2022)[1] |
| Total equity | 14.2 billion kr. (2022)[1] |
Number of employees | 6,781 (2022)[1] |
| Parent | Novo Holdings A/S |
| Website | novozymes |
Novozymes A/S is a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada.[2] Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange.[3]
On 12 December 2023, it was announced that Novozymes and Danish bioscience company Chr. Hansen had obtained regulatory approval for a merger,[4] and on the following day, the name of the combined company was revealed as Novonesis.[5]
- ^ a b c d e f "The Novozymes Report 2022" (PDF). Novozymes. 1 January 2023. Retrieved 13 August 2023.
- ^ "The Novozymes Report 2014". Novozymes. 20 January 2015. Archived from the original on 4 March 2016. Retrieved 11 April 2015.
- ^ NASDAQ OMX Nordic (5 April 2004). "NASDAQ OMX Nordic Novozymes Information". NASDAQ OMX Nordic. Retrieved 5 April 2014.
- ^ "Commission clears Novozymes and Chr. Hansen merger, subject to conditions". 12 December 2023.
- ^ "Novozymes and Chr. Hansen announce name of future combined company; Novonesis". 13 December 2023.